CCL20 and cervical cancer: Among these 42 focal CNVs, we confirmed recurrently amplified regions at 3q28 (TP63, 81%, q = 0.002) and deleted regions at 2q37.1 (CCL20, ABCB6, 47%, q = 1.33 × 10−7) and 17q25.3 (FOXK2, 21%, q = 3.05×10−5), consistent with previous studies of cervical cancer.[34] In addition to these findings, we also identified multiple novel recurrent focal amplification events, including the most significant regions 11q22.2 (YAP1, BIRC2, and BIRC3, 45%, q = 1.36 × 10−5), 22q11.23 (GSTT1, GSTTP1, and GSTTP2, 19%, q = 0.004), and 18p11.31 (EPB41L3, 17%, q = 0.05).